readthroughSign in
Oct 1, 2026Clinical readoutUpdated

Cullinan and Taiho start FDA review of zipalertinib combo for first-line lung cancer

An NDA submission under the FDA's Real-Time Oncology Review program began October 1, 2026, backed by Phase 3 REZILIENT3 progression-free survival data.

Cullinan Therapeutics, Inc. said on October 1, 2026 that it had initiated a New Drug Application submission to the FDA for zipalertinib combined with platinum-based chemotherapy, for previously untreated, locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, filed under the agency's Real-Time Oncology Review program, according to a Form 8-K. The RTOR program allows sponsors to submit clinical data in advance of the complete application to facilitate earlier review of efficacy and safety results.1 Completion of the NDA submission is expected by year-end 2026.1

The submission rests on the Phase 3 REZILIENT3 trial, which met its primary endpoint of statistically significant and clinically meaningful improvement in median progression-free survival for zipalertinib plus chemotherapy versus chemotherapy alone, with results presented at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer during a Presidential Symposium.1

Zipalertinib already holds FDA Breakthrough Therapy designation for EGFR exon 20 insertion NSCLC patients previously treated with platinum-based chemotherapy, and a separate NDA for zipalertinib monotherapy in that second-line setting remains under FDA review with a PDUFA target action date of February 27, 2027.1

Cullinan is eligible to receive a $30.0 million payment from Taiho upon U.S. approval in the previously treated setting, and up to $100.0 million upon U.S. approval for first-line use.1 Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.1

The filing follows a September 24, 2026 release in which Cullinan outlined fourth-quarter data plans for three T cell engager programs, including CLN-978, velinotamig, and CLN-049, in autoimmune and oncology indications.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.